- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants with Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis
This study looks at the long-term safety and how well a medicine called bimekizumab works for people with axial spondyloarthritis. It helps us understand its effects over a longer period.
For: Axial SpondyloarthritisHungary · Poland · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
This study is looking at the long-term safety and effectiveness of a medicine called bimekizumab for people with psoriatic arthritis. It checks how well the medicine works over time and if it causes any side effects, building on previous studies.
For: Psoriatic ArthritisItaly · Germany · Czechia - RecruitingPHASE3
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
This study is looking at a new medicine called Bimekizumab for children aged 2-18 with certain types of arthritis: enthesitis-related arthritis (including ankylosing spondylitis) and juvenile psoriatic arthritis. We want to see how the medicine works in the body.
For: Enthesitis-related Arthritis · Juvenile Psoriatic ArthritisCanada · France · Germany - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
This study is looking at a new medicine called bimekizumab for a skin condition called palmoplantar pustulosis (PPP). It wants to see if this medicine works and is safe compared to a dummy treatment.
For: Palmoplantar PustulosisUnited States · Canada · China - Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
This study investigates how inflammation, particularly involving a protein called IL-17, might link certain skin and joint conditions like psoriasis and psoriatic arthritis with depression. Researchers will use special brain scans and different anti-inflammatory medicines to understand and potentially improve depression symptoms.
For: Psoriatic Arthritis · Depression · Psoriatic PlaqueUnited Kingdom - Active not recruitingPHASE3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
This study looks at a medicine called Bimekizumab for long-term safety and how well it works in people with a type of arthritis affecting the spine, including Ankylosing Spondylitis. It's for people who have already been in related Bimekizumab studies.
For: Axial Spondyloarthritis · Ankylosing Spondylitis · r-axSpaUnited States · Belgium · Bulgaria - Active not recruitingPHASE3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
This study looks at how a new medicine, bimekizumab, affects skin cells in people with moderate to severe psoriasis. We're trying to understand how the medicine works at a very detailed level in both psoriasis and psoriatic arthritis.
For: Moderate to Severe Plaque Psoriasis · Psoriatic ArthritisUnited States · Germany · Poland - Active not recruitingPHASE3
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at the long-term safety of a treatment called bimekizumab for people with moderate to severe hidradenitis suppurativa (HS). It builds on earlier studies to see how well the treatment works and if it's safe over a longer period.
For: Hidradenitis SuppurativaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
This study looks at a new medicine called Bimekizumab for children and teenagers with moderate to severe Hidradenitis Suppurativa. It checks how the medicine works in the body and if it's safe.
For: Hidradenitis SuppurativaUnited States · Germany · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine called bimekizumab for teenagers with moderate to severe plaque psoriasis. We want to understand how it works in the body, if it's safe, and if it helps improve their skin. It's an important step in finding better treatments.
For: Moderate to Severe Plaque PsoriasisPoland · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
This study is looking at the long-term safety and effectiveness of a new medicine called bimekizumab for adults with moderate to severe hidradenitis suppurativa (HS). It's an extension of an earlier study, helping us understand how well the treatment works and if it causes any side effects over a longer time.
For: Hidradenitis SuppurativaGermany · Ireland · Greece - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
This study is testing a new medicine called bimekizumab for adults with active psoriatic arthritis. It compares bimekizumab to another medicine, risankizumab, and a dummy treatment (placebo), to see how well it works and if it's safe over 16 weeks.
For: Psoriatic ArthritisUnited States · Australia · Bulgaria